Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, and greater competition in the B-cell maturation antigen (BCMA) bispecific antibody space.
Watch
Earlier Food Introduction Dramatically Reduces Peanut, Egg, Milk Allergy Rates in Infants
July 30th 2025When updated food allergy prevention guidelines were directly provided to families, they led to earlier allergen introduction in infants and significantly reduced the prevalence of IgE-mediated peanut, egg, and cow's milk allergies.
Read More
Addressing the Hidden Burden of Polycythemia Vera: Andrew Kuykendall, MD
July 29th 2025Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.
Watch
Linvoseltamab May Bring Multiple Myeloma Care Closer to Home: Sundar Jagannath, MBBS
July 29th 2025The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community settings, according to Sundar Jagannath, MBBS.
Watch
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
July 29th 2025The FDA approved pegcetacoplan (EMPAVELI; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More
Patients With Chronic Spontaneous Urticaria Seek Better Treatment Beyond Current Options
July 28th 2025Patients with chronic spontaneous urticaria experience inadequate symptom control and significant emotional burdens despite various treatment approaches, highlighting an urgent need for more effective and sustained therapies to improve their quality of life.
Read More
Teledermatology and AI's Impact on Patient Access and Diagnostics: Hadar Avihai Lev-Tov, MD
July 28th 2025Hadar Avihai Lev-Tov, MD, asserts that advancements in teledermatology and artificial intelligence (AI)–powered diagnostic tools are crucial for improving health care efficiency and patient access within managed care.
Watch
Gefurulimab for gMG Meets Key End Points in PREVAIL Trial
July 28th 2025The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.
Read More